Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Abdominal Radiology
Erschienen in: Abdominal Radiology 11/2020

18.04.2020 | Special Section: Diffuse Liver Disease

Other types of diffuse liver disease: is there a way to do it?

Erschienen in: Abdominal Radiology | Ausgabe 11/2020

Einloggen, um Zugang zu erhalten

Abstract

There are a variety of less common diffuse liver diseases that can be asymptomatic or cause severe liver dysfunction. For the majority of them, the association of clinical, laboratory, and imaging findings are needed to narrow the differential diagnosis. In this article, we will review and describe the rarer diffuse liver diseases including drug-related liver disease, inflammatory and infectious diseases, and deposition disorders such as amyloidosis, glycogen storage disease, Wilson’s disease, and alpha-1 antitrypsin deficiency. Abdominal radiologists should be familiar with the imaging features of different types of diffuse liver diseases to help the multidisciplinary team involved in the treatment of these patients. The data related to some of these conditions are scarce and sometimes experimental, but we want to demonstrate to the reader the value of imaging techniques in their analysis and introduce the potential of new imaging methods.
Literatur
1.
Bastati N, Beer L, Mandorfer M, Poetter-Lang S, Tamandl D, Bican Y, et al. Does the Functional Liver Imaging Score Derived from Gadoxetic Acid-enhanced MRI Predict Outcomes in Chronic Liver Disease? Radiology. 2020;294(1):98-107.PubMedCrossRef
2.
Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, et al. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: Where are we? J Magn Reson Imaging. 2017;45(3):646-59.PubMedCrossRef
3.
Beer L, Mandorfer M, Bastati N, Poetter-Lang S, Tamandl D, Stoyanova DP, et al. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases. Eur Radiol. 2019;29(12):6600-10.PubMedPubMedCentralCrossRef
4.
Ngo D, Jia JB, Green CS, Gulati AT, Lall C. Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective. Insights Imaging. 2015;6(6):665-77.PubMedPubMedCentralCrossRef
5.
6.
Navarro F, Le Moine MC, Fabre JM, Belghiti J, Cherqui D, Adam R, et al. Specific vascular complications of orthotopic liver transplantation with preservation of the retrohepatic vena cava: review of 1361 cases. Transplantation. 1999;68(5):646-50.PubMedCrossRef
7.
Sharma A, Houshyar R, Bhosale P, Choi JI, Gulati R, Lall C. Chemotherapy induced liver abnormalities: an imaging perspective. Clin Mol Hepatol. 2014;20(3):317-26.PubMedPubMedCentralCrossRef
8.
Alessandrino F, Tirumani SH, Krajewski KM, Shinagare AB, Jagannathan JP, Ramaiya NH, et al. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol. 2017;72(7):521-33.PubMedCrossRef
9.
Vernuccio F, Dioguardi Burgio M, Barbiera F, Cusmà S, Badalamenti G, Midiri M, et al. CT and MR imaging of chemotherapy-induced hepatopathy. Abdom Radiol (NY). 2019;44(10):3312-24.PubMedCrossRef
10.
Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200(6):845-53.PubMedCrossRef
11.
Ramadori G, Cameron S. Effects of systemic chemotherapy on the liver. Ann Hepatol. 2010;9(2):133-43.PubMedCrossRef
12.
Berger-Kulemann V, Schima W, Baroud S, Koelblinger C, Kaczirek K, Gruenberger T, et al. Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. Eur J Surg Oncol. 2012;38(8):670-6.
13.
Wibmer A, Prusa AM, Nolz R, Gruenberger T, Schindl M, Ba-Ssalamah A. Liver failure after major liver resection: risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging. Radiology. 2013;269(3):777-86.PubMedCrossRef
14.
Adler M, Tang I, Gach MW, MacFaul G. Recurrent metastatic breast cancer presenting with portal hypertension and pseudocirrhosis. BMJ Case Rep. 2019;12(11).
15.
Vuppalanchi R, Saxena R, Storniolo AMV, Chalasani N. Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib. Hepatology. 2017;65(5):1762-4.PubMedCrossRef
16.
Jeong WK, Choi SY, Kim J. Pseudocirrhosis as a complication after chemotherapy for hepatic metastasis from breast cancer. Clin Mol Hepatol. 2013;19(2):190-4.PubMedPubMedCentralCrossRef
17.
Leshchinskiy S, Kanner C, Keating DP. Pseudocirrhosis. Abdom Radiol (NY). 2018;43(11):3197-8.PubMedCrossRef
18.
19.
DeLeve L, Kaplowitz N. Drug-Induced Liver Disease2002.
20.
Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460-6.PubMedCrossRef
21.
Overman MJ, Maru DM, Charnsangavej C, Loyer EM, Wang H, Pathak P, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010;28(15):2549-55.PubMedCrossRef
22.
Harris L, McKenna WJ, Rowland E, Holt DW, Storey GC, Krikler DM. Side effects of long-term amiodarone therapy. Circulation. 1983;67(1):45-51.PubMedCrossRef
23.
Markos J, Veronese ME, Nicholson MR, McLean S, Shevland JE. Value of hepatic computerized tomographic scanning during amiodarone therapy. Am J Cardiol. 1985;56(1):89-92.PubMedCrossRef
24.
Matsuda M, Otaka A, Tozawa T, Asano T, Ishiyama K, Hashimoto M. Analysis of computed tomography density of liver before and after amiodarone administration. Jpn J Radiol. 2018;36(5):340-4.PubMedCrossRef
25.
Kojima S, Ueno H, Takeya M, Ogawa H. Increased density of the liver and amiodarone-associated phospholipidosis. Cardiol Res Pract. 2009;2009:598940.PubMedPubMedCentralCrossRef
26.
Suzuki H, Imafuji A, Kato M, Omiya H. Dual Energy CT Assessment of Amiodarone Induced Liver Damage. Somatom Sessions2014. p. 64-5.
27.
Guigui B, Perrot S, Berry JP, Fleury-Feith J, Martin N, Métreau JM, et al. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology. 1988;8(5):1063-8.PubMedCrossRef
28.
Hussain N, Bhattacharyya A, Prueksaritanond S. Amiodarone-induced cirrhosis of liver: what predicts mortality? ISRN Cardiol. 2013;2013:617943.PubMedPubMedCentral
29.
30.
31.
De Maria M, De Simone G, Laconi A, Mercadante G, Pavone P, Rossi P. Gold storage in the liver: appearance on CT scans. Radiology. 1986;159(2):355-6.PubMedCrossRef
32.
Bluhbaum T, Frik K, Kalkbrenner H. Eine neuve Anwendungsart der Kolloide in der Rontgendiagnostik. ROFO1928. p. 18-29.
33.
Silverman PM, Ram PC, Korobkin M. CT appearance of abdominal thorotrast deposition and Thorotrast-induced angiosarcoma of the liver. J Comput Assist Tomogr. 1983;7(4):655-8.PubMedCrossRef
34.
Macmahon HE, Murphy AS, Bates MI. Endothelial-Cell Sarcoma of Liver Following Thorotrast Injections. Am J Pathol. 1947;23(4):585-611.PubMedPubMedCentral
35.
Kiyosawa K, Akahane Y, Miyazaki Y, Sato K, Shirai T, Mizuno T, et al. Resection of thorotrast-induced cholangiocarcinoma. Am J Gastroenterol. 1983;78(7):429-33.PubMed
36.
Ito Y, Kojiro M, Nakashima T, Mori T. Pathomorphologic characteristics of 102 cases of thorotrast-related hepatocellular carcinoma, cholangiocarcinoma, and hepatic angiosarcoma. Cancer. 1988;62(6):1153-62.PubMedCrossRef
37.
Stojkovic M, Müller J, Junghanss T, Weber TF. Radiological Diagnoses in the Context of Emigration: Infectious diseases. Rofo. 2018;190(2):121-33.PubMedCrossRef
38.
Mergo PJ, Ros PR, Buetow PC, Buck JL. Diffuse disease of the liver: radiologic-pathologic correlation. Radiographics. 1994;14(6):1291-307.PubMedCrossRef
39.
Mortelé KJ, Segatto E, Ros PR. The infected liver: radiologic-pathologic correlation. Radiographics. 2004;24(4):937-55.PubMedCrossRef
40.
Toda KS, Kikuchi L, Chagas AL, Tanigawa RY, Paranaguá-Vezozzo DC, Pfiffer T, et al. Hepatocellular Carcinoma Related to Schistosoma mansoni Infection: Case Series and Literature Review. J Clin Transl Hepatol. 2015;3(4):260-4.PubMedPubMedCentralCrossRef
41.
42.
Cerri GG, Alves VA, Magalhães A. Hepatosplenic schistosomiasis mansoni: ultrasound manifestations. Radiology. 1984;153(3):777-80.PubMedCrossRef
43.
Mamone G, Cortis K, Sarah A, Caruso S, Miraglia R. Hepatic morphology abnormalities: beyond cirrhosis. Abdom Radiol (NY). 2018;43(7):1612-26.PubMedCrossRef
44.
Bezerra AS, D’Ippolito G, Caldana RP, Leopoldino DD, Batista GR, Borges DR, et al. Differentiating cirrhosis and chronic hepatosplenic schistosomiasis using MRI. AJR Am J Roentgenol. 2008;190(3):W201-7.PubMedCrossRef
45.
Olveda DU, Olveda RM, Lam AK, Chau TN, Li Y, Gisparil AD, et al. Utility of Diagnostic Imaging in the Diagnosis and Management of Schistosomiasis. Clin Microbiol. 2014;3(2).
46.
Fetzer DT, Rees MA, Dasyam AK, Tublin ME. Hepatic sarcoidosis in patients presenting with liver dysfunction: imaging appearance, pathological correlation and disease evolution. Eur Radiol. 2016;26(9):3129-37.PubMedCrossRef
47.
Tana C, Schiavone C, Ticinesi A, Ricci F, Giamberardino MA, Cipollone F, et al. Ultrasound imaging of abdominal sarcoidosis: State of the art. World J Clin Cases. 2019;7(7):809-18.PubMedPubMedCentralCrossRef
48.
Masuda K, Takenaga S, Morikawa K, Kano A, Ojiri H. Hepatic sarcoidosis with atypical radiological manifestations: A case report. Radiol Case Rep. 2018;13(5):936-9.PubMedPubMedCentralCrossRef
49.
Peters B, Vanhoenacker FM, Bernard P, Van Dijck H, Van Overbeke L. Hepatosplenic Sarcoidosis Complicated by Liver Cirrhosis. J Belg Soc Radiol. 2015;99(2):53-7.PubMedPubMedCentralCrossRef
50.
Palmucci S, Torrisi SE, Caltabiano DC, Puglisi S, Lentini V, Grassedonio E, et al. Clinical and radiological features of extra-pulmonary sarcoidosis: a pictorial essay. Insights Imaging. 2016;7(4):571-87.PubMedPubMedCentralCrossRef
51.
Ch’ng LS, Amzar H, Ghazali KC, Siam F. Imaging appearances of hepatic tuberculosis: experience with 12 patients. Clin Radiol. 2018;73(3):321.e11-.e16.
52.
Schininà V, Albarello F, Cristofaro M, Di Stefano F, Fusco N, Cuzzi G, et al. Diagnostic imaging of hepatic tuberculosis: case series. Int J Tuberc Lung Dis. 2018;22(7):779-87.PubMedCrossRef
53.
Deshpande SS, Joshi AR, Phajlani SA. Computed tomographic features of abdominal tuberculosis: unmask the impersonator! Abdom Radiol (NY). 2019;44(1):11-21.PubMedCrossRef
54.
55.
Indiran V, Vinoth Kumar R. ‘Frosted liver’ appearance. Abdom Radiol (NY). 2017;42(10):2587.PubMedCrossRef
56.
Jain N, Rissam HK, Puri SK, Chauhan U. The “frosted liver” appearance in hepatic tuberculosis: a rare presentation. BJR Case Rep. 2016;2(4):20150367.PubMedPubMedCentral
57.
Kakkar C, Polnaya AM, Koteshwara P, Smiti S, Rajagopal KV, Arora A. Hepatic tuberculosis: a multimodality imaging review. Insights Imaging. 2015;6(6):647-58.PubMedPubMedCentralCrossRef
58.
Doppman JL, Cornblath M, Dwyer AJ, Adams AJ, Girton ME, Sidbury J. Computed tomography of the liver and kidneys in glycogen storage disease. J Comput Assist Tomogr. 1982;6(1):67-71.PubMedCrossRef
59.
Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics. 2000;105(1):e10.PubMedCrossRef
60.
Shin YS. Glycogen storage disease: clinical, biochemical, and molecular heterogeneity. Semin Pediatr Neurol. 2006;13(2):115-20.PubMedCrossRef
61.
Labrune P, Trioche P, Duvaltier I, Chevalier P, Odièvre M. Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr. 1997;24(3):276-9.PubMedCrossRef
62.
63.
Oterdoom LH, Verweij KE, Biermann K, Langeveld M, van Buuren HR. Hepatocellular Adenomas and Carcinoma in Asymptomatic, Non-Cirrhotic Type III Glycogen Storage Disease. J Gastrointestin Liver Dis. 2015;24(4):515-8.PubMedCrossRef
64.
Iijima H, Moriwaki Y, Yamamoto T, Takahashi S, Nishigami T, Hada T. Spontaneous regression of hepatic adenoma in a patient with glycogen storage disease type I after hemodialysis: ultrasonographic and CT findings. Intern Med. 2001;40(9):891-5.PubMedCrossRef
65.
66.
MacDonald MJ, Hasan NM, Ansari IU, Longacre MJ, Kendrick MA, Stoker SW. Discovery of a Genetic Metabolic Cause for Mauriac Syndrome in Type 1 Diabetes. Diabetes. 2016;65(7):2051-9.PubMedCrossRef
67.
Sweetser S, Kraichely RE. The bright liver of glycogenic hepatopathy. Hepatology. 2010;51(2):711-2.PubMedCrossRef
68.
Murata F, Horie I, Ando T, Isomoto E, Hayashi H, Akazawa S, et al. A case of glycogenic hepatopathy developed in a patient with new-onset fulminant type 1 diabetes: the role of image modalities in diagnosing hepatic glycogen deposition including gradient-dual-echo MRI. Endocr J. 2012;59(8):669-76.PubMedCrossRef
69.
Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging. 1995;5(3):281-5.PubMedCrossRef
70.
Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288(2):E462-8.PubMedCrossRef
71.
Qayyum A. MR spectroscopy of the liver: principles and clinical applications. Radiographics. 2009;29(6):1653-64.PubMedCrossRef
72.
Machann J, Stefan N, Schick F. (1)H MR spectroscopy of skeletal muscle, liver and bone marrow. Eur J Radiol. 2008;67(2):275-84.PubMedCrossRef
73.
74.
75.
Roser W, Beckmann N, Wiesmann U, Seelig J. Absolute quantification of the hepatic glycogen content in a patient with glycogen storage disease by 13C magnetic resonance spectroscopy. Magn Reson Imaging. 1996;14(10):1217-20.PubMedCrossRef
76.
Kishore P, Gabriely I, Cui MH, Di Vito J, Gajavelli S, Hwang JH, et al. Role of hepatic glycogen breakdown in defective counterregulation of hypoglycemia in intensively treated type 1 diabetes. Diabetes. 2006;55(3):659-66.PubMedCrossRef
77.
Hwang JH, Perseghin G, Rothman DL, Cline GW, Magnusson I, Petersen KF, et al. Impaired net hepatic glycogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. A 13C nuclear magnetic resonance spectroscopy study. J Clin Invest. 1995;95(2):783-7.
78.
Roden M, Perseghin G, Petersen KF, Hwang JH, Cline GW, Gerow K, et al. The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans. J Clin Invest. 1996;97(3):642-8.PubMedPubMedCentralCrossRef
79.
Mishkovsky M, Comment A, Gruetter R. In vivo detection of brain Krebs cycle intermediate by hyperpolarized magnetic resonance. J Cereb Blood Flow Metab. 2012;32(12):2108-13.PubMedPubMedCentralCrossRef
80.
Jones KM, Pollard AC, Pagel MD. Clinical applications of chemical exchange saturation transfer (CEST) MRI. J Magn Reson Imaging. 2018;47(1):11-27.PubMedCrossRef
81.
Chen SZ, Yuan J, Deng M, Wei J, Zhou J, Wáng YX. Chemical exchange saturation transfer (CEST) MR technique for in-vivo liver imaging at 3.0 tesla. Eur Radiol. 2016;26(6):1792-800.
82.
83.
Tanzi RE, Petrukhin K, Chernov I, Pellequer JL, Wasco W, Ross B, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1993;5(4):344-50.PubMedCrossRef
84.
Ala A, Schilsky ML. Wilson disease: pathophysiology, diagnosis, treatment, and screening. Clin Liver Dis. 2004;8(4):787-805, viii.
85.
Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, et al. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 2003;23(3):139-42.PubMedCrossRef
86.
Cheon JE, Kim IO, Seo JK, Ko JS, Lee JM, Shin CI, et al. Clinical application of liver MR imaging in Wilson’s disease. Korean J Radiol. 2010;11(6):665-72.PubMedPubMedCentralCrossRef
87.
Akhan O, Akpinar E, Karcaaltincaba M, Haliloglu M, Akata D, Karaosmanoglu AD, et al. Imaging findings of liver involvement of Wilson’s disease. Eur J Radiol. 2009;69(1):147-55.PubMedCrossRef
88.
Boll DT, Merkle EM. Diffuse liver disease: strategies for hepatic CT and MR imaging. Radiographics. 2009;29(6):1591-614.PubMedCrossRef
89.
Fritzsch D, Reiss-Zimmermann M, Trampel R, Turner R, Hoffmann KT, Schäfer A. Seven-tesla magnetic resonance imaging in Wilson disease using quantitative susceptibility mapping for measurement of copper accumulation. Invest Radiol. 2014;49(5):299-306.PubMedCrossRef
90.
Unal E, Idilman IS, Karçaaltıncaba M. Multiparametric or practical quantitative liver MRI: towards millisecond, fat fraction, kilopascal and function era. Expert Rev Gastroenterol Hepatol. 2017;11(2):167-82.PubMedCrossRef
91.
92.
Czeyda-Pommersheim F, Hwang M, Chen SS, Strollo D, Fuhrman C, Bhalla S. Amyloidosis: Modern Cross-sectional Imaging. Radiographics. 2015;35(5):1381-92.PubMedCrossRef
93.
Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387(10038):2641-54.PubMedCrossRef
94.
Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid. 2014;21(4):221-4.PubMedCrossRef
95.
Esplin BL, Gertz MA. Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol. 2013;38(2):53-96.PubMedCrossRef
96.
Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79(7):1817-22.PubMedCrossRef
97.
Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161(4):525-32.PubMedPubMedCentralCrossRef
98.
Hemminki K, Li X, Försti A, Sundquist J, Sundquist K. Incidence and survival in non-hereditary amyloidosis in Sweden. BMC Public Health. 2012;12:974.PubMedPubMedCentralCrossRef
99.
Monzawa S, Tsukamoto T, Omata K, Hosoda K, Araki T, Sugimura K. A case with primary amyloidosis of the liver and spleen: radiologic findings. Eur J Radiol. 2002;41(3):237-41.PubMedCrossRef
100.
Scott PP, Scott WW, Siegelman SS. Amyloidosis: an overview. Semin Roentgenol. 1986;21(2):103-12.PubMedCrossRef
101.
Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047-60.PubMedCrossRef
102.
103.
Gertz MA, Kyle RA. Hepatic amyloidosis: clinical appraisal in 77 patients. Hepatology. 1997;25(1):118-21.PubMedCrossRef
104.
Kim SH, Han JK, Lee KH, Won HJ, Kim KW, Kim JS, et al. Abdominal amyloidosis: spectrum of radiological findings. Clin Radiol. 2003;58(8):610-20.PubMedCrossRef
105.
Benson L, Hemmingsson A, Ericsson A, Jung B, Sperber G, Thuomas KA, et al. Magnetic resonance imaging in primary amyloidosis. Acta Radiol. 1987;28(1):13-5.PubMedCrossRef
106.
Møller JM, Santoni-Rugiu E, Chabanova E, Løgager V, Hansen AB, Thomsen HS. Magnetic resonance imaging with liver-specific contrast agent in primary amyloidosis and intrahepatic cholestasis. Acta Radiol. 2007;48(2):145-9.PubMedCrossRef
107.
Castaño A, Bokhari S, Brannagan TH, Wynn J, Maurer MS. Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): a case report and literature review. Amyloid. 2012;19(1):41-6.PubMedCrossRef
108.
Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014;15(11):1289-98.PubMedCrossRef
109.
Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2013;54(2):213-20.PubMedCrossRef
110.
Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR, Di Carli MF, et al. Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging. 2014;41(9):1652-62.PubMedCrossRef
111.
Guillaud O, Dumortier J, Traclet J, Restier L, Joly P, Chapuis-Cellier C, et al. Assessment of liver fibrosis by transient elastography (Fibroscan. Clin Res Hepatol Gastroenterol. 2019;43(1):77-81.PubMedCrossRef
112.
Kim RG, Nguyen P, Bettencourt R, Dulai PS, Haufe W, Hooker J, et al. Magnetic resonance elastography identifies fibrosis in adults with alpha-1 antitrypsin deficiency liver disease: a prospective study. Aliment Pharmacol Ther. 2016;44(3):287-99.PubMedCrossRef
113.
Reiter R, Wetzel M, Hamesch K, Strnad P, Asbach P, Haas M, et al. Comparison of non-invasive assessment of liver fibrosis in patients with alpha1-antitrypsin deficiency using magnetic resonance elastography (MRE), acoustic radiation force impulse (ARFI) Quantification, and 2D-shear wave elastography (2D-SWE). PLoS One. 2018;13(4):e0196486.PubMedPubMedCentralCrossRef
114.
Hoy AM, Fallowfield JA. Editorial: non-invasive assessment of hepatic fibrosis in alpha-1 antitrypsin deficiency using magnetic resonance elastography. Aliment Pharmacol Ther. 2016;44(6):644-5.PubMedCrossRef
Metadaten
Titel
Other types of diffuse liver disease: is there a way to do it?
Publikationsdatum
18.04.2020
Erschienen in
Abdominal Radiology / Ausgabe 11/2020
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-020-02530-6

Weitere Artikel der Ausgabe 11/2020

Abdominal Radiology 11/2020 Zur Ausgabe

Interventional Radiology

CT-guided cryoablation of renal cancer: radiation burden and the associated risk of secondary cancer from procedural- and follow-up imaging

Kidneys, Ureters, Bladder, Retroperitoneum

Differential diagnosis of hypervascular ultra-small renal cell carcinoma and renal angiomyolipoma with minimal fat in early stage by using thin-section multidetector computed tomography

Review

Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound

Interventional Radiology

Impact of PTFE-covered stent position and extension on TIPS patency

Interventional Radiology

Percutaneous intraductal radiofrequency ablation combined with biliary stent placement for treatment of malignant biliary obstruction

Classics in Abdominal Radiology

The tobacco flecks

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

S3-Leitlinie zu Pankreaskrebs aktualisiert

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

13.04.2024 | Klinik aktuell | Kongressbericht | Nachrichten

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

08.04.2024 | Andrologie | Nachrichten

Wie toxische Männlichkeit der Gesundheit von Männern schadet
weitere anzeigen

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen